CClinicalTrials.gg
CompletedNCT03110393Updated Jan 8, 2018

Ambu®AuraGain™ Versus I-gel® in Obese Patients

An interventional study of Ambu AuraGain and Intersurgical i-gel in Obese, sponsored by Schulthess Klinik. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-08.

Sponsored by Schulthess Klinik · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is the randomized comparison of two laryngeal mask (Intersurgical i-gel® and Ambu®AuraGain™) in obese patients

Read the detailed description

Since the incidence of a difficult intubation lies between 4.5% -7.5%, the search for alternative airway devices has been forced in the past.

As an option, the laryngeal mask is suitable, which has been used as a universal airway with a high degree of safety in routine anesthesia.

There are numbers of different laryngeal masks available which have the characteristic to insert an endotracheal tube through the ventilation lumen.

The indications for these laryngeal masks can be extended due to continuous improvements in the laryngeal masks, these laryngeal masks can also be used in obese patients. Obese patients generally have a 4-fold increased risk of a difficult airway, and a BMI over 35 is a predictor of a difficult tracheal intubation.

There are no studies comparing the Intersurgical i-gel® Laryngeal Mask and the Ambu®AuraGain ™ Laryngeal Mask in obese patients.

02

Conditions studied

  • Obese

Browse trials for

Keywords

  • Obese
  • Laryngeal Mask Airway
  • Anaesthesia
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 44 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Schulthess Klinik is the lead sponsor of 52 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • ASA 1-3
  • Shoulder-/Elbow-/Hip-/Knee- or Foot - Surgery
  • Signed informed consent
  • BMI > 35kg/m2

Exclusion criteria

Exclusion Criteria:

  • Non-sober patients (last meal \<6 h)
  • Symptomatic reflux disease
  • Hiatus hernia
  • Significant cardiovascular risk factors
  • Severe COPD
  • Gastric band or gastric bypass
  • Disease which allows an accurate examination of the physicians (e.g. neuromuscular, mental, metabolic disease)
  • Drug or drug abuse in the recent past
  • Legal immaturity (incompetence)
  • Acute disease, which calls into question the narcotic potential
  • Patients with whom the use of a laryngeal mask is contraindicated or otherwise not possible
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Ambu® AuraGain™

    Intervention with Ambu® AuraGain™Laryngeal Mask

    Device: Ambu AuraGain

  • Active comparator
    Intersurgical i-gel®

    Intervention with Intersurgical i-gel® Laryngeal Mask

    Device: Intersurgical i-gel

Interventions

  • DeviceAmbu AuraGain

    Insert and intubation of an Ambu® AuraGain™ laryngeal mask

  • DeviceIntersurgical i-gel

    Insert and intubation of an Intersurgical i-gel®

06

What researchers measure

Primary outcomes

  1. Time of successful intubation

    Measurement of a fiberoptic intubation with the laryngeal mask. Start: Insertion of the fiberoptic into the larynxmask until the intubation has been done and after the fiberoptic has been removed.

    Time frame: intraoperative

Secondary outcomes

  1. Number of Insertions (of the laryngeal mask)

    Number of insertion attempts will be registered

    Time frame: intraoperative

  2. Time of insertion

    The time of Insertion of the laryngeal mask will be recorded.

    Time frame: intraoperative

  3. Number of insertion attempts

    Number of insertions with the stomach tube will be registered

    Time frame: intraoperative

  4. Gastric volume

    Measurement of the gastric volume

    Time frame: intraoperative

  5. Positioning of the gastric probe

    Determination of the position of the gastric probe after successful insertion by stethoscope.

    Time frame: intraoperative

  6. Successful Ventilation

    Detection of a successful Ventilation. There are two options: a tidal volume \> 6mL/kg lean body mass or endtidal pCO2 \< 6.7kPa

    Time frame: intraoperative

  7. Oropharyngeal leak pressure of the Ambu®AuraGain ™

    The oropharyngeal leak pressure of the AuraGain™ is measured with a measured cuff volume of 60cmH2O

    Time frame: intraoperative

  8. Oropharyngeal leak pressure of the Intersurgical i-gel®

    The oropharyngeal leak pressure of the Intersurgical i-gel® is measured.

    Time frame: intraoperative

  9. Measurement of blood pressure

    Measurement of blood pressure during 5min (1 measurement / minute).

    Time frame: intraoperative

  10. Measurement of oxygen saturation

    Measurement oxygen saturation during 5min (1 measurement / minute).

    Time frame: intraoperative

  11. Measurement of heart rate

    Measurement of heart rate during 5min (1 measurement / minute).

    Time frame: intraoperative

  12. Maximum ventilation pressure

    The maximum ventilation pressure is measured, which must be applied in order to adequately ventilate the patients. This is measured over 5 minutes

    Time frame: intraoperative

  13. Measurement CO2 (kPa):

    The exhaled CO2 is determined continuously.

    Time frame: intraoperative

  14. Number of intubation attempts

    The number of intubation attempts until successful intubation is recorded.

    Time frame: intraoperative

  15. Reasons for the unsuccessful intubation

    The reasons are listed in tabular form.

    Time frame: intraoperative

  16. Number of esophageal intubations

    The number of esophageal intubations is measured.

    Time frame: intraoperative

  17. Resistance (for an EET):

    The resistance is measured with a score of 1- 4. 1: simple passage, no resistance, 2: little resistance for the passage, 3: significant resistance for the passage, 4: passage not possible

    Time frame: intraoperative

  18. Location of the mask (Brimacombe)

    The position of the mask is determined by pushing the fiber optic to a maximum of 1cm over the LMA and then using the Brimacombe score.

    Time frame: intraoperative

  19. Swallowing (no / little / medium / strong)

    The swallowing difficulties are questioned preoperatively and postoperatively (5 (± 1) h after anesthesia end).

    Time frame: 5hour postoperative

  20. Throat pain (no / little / medium / strong)

    The throat pain is questioned preoperatively and postoperatively (5 (± 1) h after anesthesia end).

    Time frame: 5hour postoperative

  21. Hoarseness (no / little / medium / strong)

    The swallowing difficulties, the throat pain and the hoarseness are questioned preoperatively and postoperatively (5 (± 1) h after anesthesia end).

    Time frame: 5hour postoperative

  22. Blood on laryngeal mask after intubation

    Determination of the visible blood on the laryngeal mask after removal (no, little, much).

    Time frame: intraoperative

07

Study locations

1 site
  • Schulthess Klinik
    Zürich, 8008, Switzerland
08

References and documents

Publications

  • Moser B, Keller C, Audige L, Dave MH, Bruppacher HR. Fiberoptic intubation of severely obese patients through supraglottic airway: A prospective, randomized trial of the Ambu(R) AuraGain laryngeal mask vs the i-gel airway. Acta Anaesthesiol Scand. 2019 Feb;63(2):187-194. doi: 10.1111/aas.13242. Epub 2018 Aug 8. PubMed 30088266 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03110393
Lead sponsor
Schulthess Klinik
Responsible party
Berthold Moser (Principal Investigator, Schulthess Klinik) — Principal investigator
First posted
Apr 12, 2017
Start date
Apr 20, 2017
Primary completion
Sep 6, 2017
Completion
Sep 6, 2017
Last update
Jan 8, 2018

Study contacts

Berthold Berthold, MD
principal investigator · Schulthess Klinik

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion